The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

A new study from the University of Birmingham has shown that Faecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection. Published ...

1. Fidaxomicin, a newer treatment for C. diff, was often the most cost-effective treatment, though the findings were not definitive, as results from the individual studies largely varied based on the ...

Researchers at the American Society for Microbiology’s 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy have reported that low-dose antibiotic treatments appear to be as effective ...

(Reuters) - Drugmakers racing to develop medicines and vaccines to combat a germ that ravages the gut and kills thousands have a new challenger: the human stool. For patients hit hardest by the ...

MGB Biopharma, a biopharmaceutical company which has licensed technology from Strathclyde, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals is celebrating the second anniversary of the launch of REBYOTA ® (fecal microbiota, live – jslm), the first microbiome-based therapy approved ...